Creative Planning’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Creative Planning's NBIX Position: Q3 2026 in Review
Creative Planning increased its Neurocrine Biosciences (NBIX) stake by 0.41% in Q3 2026, buying an estimated $50.8K and bringing the position to 77,134 shares worth $10.9M. The position accounts for 0.01% of the portfolio, ranked #908.
Creative Planning first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. The position peaked at $12.9M in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Creative Planning held 77,134 shares of Neurocrine Biosciences worth $10.9M as of Q3 2026.
- Creative Planning bought 316 Neurocrine Biosciences shares in Q3 2026, an estimated $50.8K.
- Neurocrine Biosciences made up 0.01% of Creative Planning's portfolio in Q3 2026, its #908 holding.
- Creative Planning first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
- Creative Planning's Neurocrine Biosciences position peaked at $12.9M in Q2 2026.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.